An Open-label, Extension Study to Assess the Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children Who Completed the OTR3001 Study

Trial Profile

An Open-label, Extension Study to Assess the Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children Who Completed the OTR3001 Study

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Oxycodone (Primary)
  • Indications Cancer pain; Pain
  • Focus Adverse reactions
  • Sponsors Purdue Pharma
  • Most Recent Events

    • 16 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 May 2014 Planned number of patients changed from 135 to 32 as reported by ClinicalTrials.gov record.
    • 07 May 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top